Noubar Afeyan Sells 10,000 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan sold 10,000 shares of Moderna stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $76.00, for a total value of $760,000.00. Following the completion of the transaction, the director now owns 2,146,931 shares in the company, valued at $163,166,756. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Noubar Afeyan also recently made the following trade(s):

• On Wednesday, October 25th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $76.99, for a total value of $769,900.00.
• On Wednesday, October 11th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $103.30, for a total value of $1,549,500.00.
• On Wednesday, October 4th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $102.72, for a total value of $1,540,800.00.
• On Wednesday, September 27th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $98.96, for a total value of $989,600.00.
• On Wednesday, September 20th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $104.74, for a total value of $1,571,100.00.
• On Wednesday, September 13th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $109.70, for a total value of $1,645,500.00.
• On Wednesday, September 6th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $107.61, for a total value of $1,614,150.00.
• On Wednesday, August 30th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $115.46, for a total value of $1,731,900.00.
• On Wednesday, August 23rd, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $115.51, for a total value of $1,732,650.00.
• On Wednesday, August 16th, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $97.56, for a total value of $975,600.00.

Moderna Stock Up 8.8 %

NASDAQ:MRNA opened at $77.53 on Friday. The stock’s fifty day moving average price is $97.80 and its two-hundred day moving average price is $113.94. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $217.25. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.16 and a current ratio of 2.46. The company has a market cap of $29.51 billion, a price-to-earnings ratio of -8.29 and a beta of 1.70.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, August 3rd. The company reported ($3.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.84) by $0.22. Moderna had a negative return on equity of 20.27% and a negative net margin of 38.00%. The firm had revenue of $344.00 million for the quarter, compared to the consensus estimate of $307.67 million. During the same quarter in the prior year, the business earned $5.24 EPS. The business’s revenue for the quarter was down 92.8% compared to the same quarter last year. On average, analysts anticipate that Moderna, Inc. will post -4.63 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on MRNA shares. The Goldman Sachs Group lowered their price target on Moderna from $269.00 to $231.00 and set a “buy” rating on the stock in a research note on Friday. Jefferies Financial Group decreased their price objective on Moderna from $275.00 to $175.00 in a report on Friday, August 4th. HSBC raised Moderna from a “reduce” rating to a “hold” rating and decreased their price objective for the company from $89.00 to $69.00 in a report on Friday. TD Cowen downgraded Moderna from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $145.00 to $125.00 in a report on Friday, August 4th. Finally, William Blair initiated coverage on Moderna in a report on Monday, July 24th. They set a “market perform” rating and a $136.28 price objective on the stock. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $143.02.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of MRNA. First Pacific Financial acquired a new position in Moderna during the 3rd quarter worth $27,000. ICA Group Wealth Management LLC bought a new stake in shares of Moderna during the 4th quarter valued at $27,000. GHP Investment Advisors Inc. raised its position in shares of Moderna by 208.3% during the 1st quarter. GHP Investment Advisors Inc. now owns 185 shares of the company’s stock valued at $28,000 after acquiring an additional 125 shares during the last quarter. Close Asset Management Ltd raised its position in shares of Moderna by 1,250.0% during the 2nd quarter. Close Asset Management Ltd now owns 270 shares of the company’s stock valued at $33,000 after acquiring an additional 250 shares during the last quarter. Finally, Stone House Investment Management LLC bought a new stake in shares of Moderna during the 1st quarter valued at $36,000. Institutional investors and hedge funds own 64.51% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.